Bloomfield C D, Kersey J H, Brunning R D, Gajl-Peczalska K J
Cancer Treat Rep. 1977 Sep;61(6):963-70.
Neoplastic tissues from 75 adults with non-Hodgkin's malignant lymphoma, histologically classified according to the Rappaport schema, were studied for B- and T-lymphocyte surface markers. All nodular poorly differentiated lymphocytic lymphomas and diffuse well-differentiated lymphocytic lymphomas were B cell. Of 30 diffuse poorly differentiated lymphocytic lymphomas 16 were B, five were T, and nine were "null"; of ten diffuse histiocytic lymphomas, seven were B and three were null. In patients with diffuse lymphoma, those whose malignant cells demonstrated B markers survived significantly longer than those whose malignant cells demonstrated no markers. The prognostic capabilities of the Rappaport histologic classification and surface marker studies were compared. For patients with diffuse lymphomas, classification as B or null more accurately predicted survival than did identification as lymphocytic or histiocytic. However, survival was best predicted by a classification combining the Rappaport histologic scheme with surface marker studies.
对75例非霍奇金恶性淋巴瘤成年患者的肿瘤组织进行了研究,这些肿瘤组织根据拉帕波特分类法进行了组织学分类,研究其B淋巴细胞和T淋巴细胞表面标志物。所有结节性低分化淋巴细胞性淋巴瘤和弥漫性高分化淋巴细胞性淋巴瘤均为B细胞型。在30例弥漫性低分化淋巴细胞性淋巴瘤中,16例为B细胞型,5例为T细胞型,9例为“无标记”型;在10例弥漫性组织细胞性淋巴瘤中,7例为B细胞型,3例为无标记型。在弥漫性淋巴瘤患者中,恶性细胞显示B标志物的患者比恶性细胞无标志物的患者存活时间明显更长。比较了拉帕波特组织学分类和表面标志物研究的预后能力。对于弥漫性淋巴瘤患者,分类为B细胞型或无标记型比分类为淋巴细胞型或组织细胞型更能准确预测生存情况。然而,将拉帕波特组织学分类与表面标志物研究相结合的分类方法对生存情况的预测效果最佳。